Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Earl, Helena M"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
Wyświetlanie 61-73 z 73
Tytuł:
OPTIMA (Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis): A prospective trial to validate the predictive utility and cost-effectiveness of gene expression test-directed chemotherapy decisions.
Autorzy:
Francis, Adele
Stein, Robert C.
Marshall, Andrea
Rea, Daniel W.
Cameron, David A.
Macpherson, Iain R.
Earl, Helena M.
Poole, Christopher J.
Hall, Peter S.
Bartlett, John M.S.
Rooshenas, Leila
Morgan, Adrienne
Harmer, Victoria
Donovan, Jenny
Hulme, Claire
McCabe, Christopher
Pinder, Sarah E.
Hughes-Davies, Luke
Makris, Andreas
Dunn, Janet A.
Pokaż więcej
Temat:
BREAST cancer patients
BREAST cancer surgery
BREAST cancer treatment
GENE expression
CANCER chemotherapy
Źródło:
European Journal of Surgical Oncology; May2016, Vol. 42 Issue 5, pS9-S10, 1p
Czasopismo naukowe
Szczegóły
Tytuł:
A nested cohort study of 6,248 early breast cancer patients treated in neoadjuvant and adjuvant chemotherapy trials investigating the prognostic value of chemotherapy-related toxicities.
Autorzy:
Abraham JE; Department of Oncology, Addenbrooke's Hospital, University of Cambridge, Hills Road, Box 193, Cambridge, CB2 0QQ, UK. .; NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre, Box 277, Hills Road, Cambridge, CB2 0QQ, UK. .; Strangeways Research Laboratory, University of Cambridge, 2 Worts Causeway, Cambridge, CB1 8RN, UK. .; Cambridge Breast Unit and Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge, CB2 0QQ, UK. .
Hiller L; Warwick Clinical Trials Unit, University of Warwick, Gibbet Hill Road, Coventry, CV4 7AL, UK. .
Dorling L; Strangeways Research Laboratory, University of Cambridge, 2 Worts Causeway, Cambridge, CB1 8RN, UK. .
Vallier AL; Department of Oncology, Cambridge Cancer Trials Centre, Box 279 (S4), Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK. .; Cambridge Breast Unit and Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge, CB2 0QQ, UK. .
Dunn J; Warwick Clinical Trials Unit, University of Warwick, Gibbet Hill Road, Coventry, CV4 7AL, UK. .
Bowden S; Cancer Research UK Clinical Trials Unit, Institute for Cancer Studies, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK. .
Ingle S; Department of Oncology, Addenbrooke's Hospital, University of Cambridge, Hills Road, Box 193, Cambridge, CB2 0QQ, UK. .; NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre, Box 277, Hills Road, Cambridge, CB2 0QQ, UK. .; Department of Oncology, Cambridge Cancer Trials Centre, Box 279 (S4), Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK. .
Jones L; Department of Oncology, Addenbrooke's Hospital, University of Cambridge, Hills Road, Box 193, Cambridge, CB2 0QQ, UK. .; NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre, Box 277, Hills Road, Cambridge, CB2 0QQ, UK. .; Cambridge Breast Unit and Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge, CB2 0QQ, UK. .
Hardy R; Department of Oncology, Addenbrooke's Hospital, University of Cambridge, Hills Road, Box 193, Cambridge, CB2 0QQ, UK. .; NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre, Box 277, Hills Road, Cambridge, CB2 0QQ, UK. .; Department of Oncology, Cambridge Cancer Trials Centre, Box 279 (S4), Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK. .
Twelves C; Level 4, Leeds Institute of Cancer and Pathology and Leeds Experimental Cancer Medical Centre, St James Institute of Oncology, Beckett Street, Leeds, LS9 7TF, UK. .
Poole CJ; Warwick Clinical Trials Unit, University of Warwick, Gibbet Hill Road, Coventry, CV4 7AL, UK. .
Pharoah PD; Strangeways Research Laboratory, University of Cambridge, 2 Worts Causeway, Cambridge, CB1 8RN, UK. .
Caldas C; Department of Oncology, Addenbrooke's Hospital, University of Cambridge, Hills Road, Box 193, Cambridge, CB2 0QQ, UK. .; NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre, Box 277, Hills Road, Cambridge, CB2 0QQ, UK. .; Cambridge Breast Unit and Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge, CB2 0QQ, UK. .; Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK. .
Earl HM; Department of Oncology, Addenbrooke's Hospital, University of Cambridge, Hills Road, Box 193, Cambridge, CB2 0QQ, UK. .; NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre, Box 277, Hills Road, Cambridge, CB2 0QQ, UK. .; Cambridge Breast Unit and Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge, CB2 0QQ, UK. .
Pokaż więcej
Źródło:
BMC medicine [BMC Med] 2015 Dec 29; Vol. 13, pp. 306. Date of Electronic Publication: 2015 Dec 29.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Agents/*adverse effects
Breast Neoplasms/*drug therapy
Chemotherapy, Adjuvant/*adverse effects
Antineoplastic Agents/therapeutic use ; Breast Neoplasms/mortality ; Case-Control Studies ; Chemotherapy, Adjuvant/methods ; Cohort Studies ; Disease-Free Survival ; Female ; Humans ; Middle Aged ; Prognosis
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
A Bayesian adaptive design for biomarker trials with linked treatments.
Autorzy:
Wason JM; MRC Biostatistics Unit Hub for Trials Methodology Research, Cambridge, UK.
Abraham JE; Department of Oncology, University of Cambridge and NIHR Cambridge Biomedical Research Centre, Cambridge, UK.; Cambridge Breast Unit, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK.; Cambridge Experimental Cancer Medicine Centre, Cambridge, UK.
Baird RD; Department of Oncology, University of Cambridge and NIHR Cambridge Biomedical Research Centre, Cambridge, UK.; Cambridge Breast Unit, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK.; Cambridge Experimental Cancer Medicine Centre, Cambridge, UK.
Gournaris I; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, UK.
Vallier AL; Cambridge Breast Unit, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK.
Brenton JD; Department of Oncology, University of Cambridge and NIHR Cambridge Biomedical Research Centre, Cambridge, UK.; Cambridge Experimental Cancer Medicine Centre, Cambridge, UK.; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, UK.
Earl HM; Department of Oncology, University of Cambridge and NIHR Cambridge Biomedical Research Centre, Cambridge, UK.; Cambridge Breast Unit, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK.; Cambridge Experimental Cancer Medicine Centre, Cambridge, UK.
Mander AP; MRC Biostatistics Unit Hub for Trials Methodology Research, Cambridge, UK.
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2015 Sep 01; Vol. 113 (5), pp. 699-705. Date of Electronic Publication: 2015 Aug 11.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Clinical Trials, Phase II as Topic/*methods
Randomized Controlled Trials as Topic/*methods
Antineoplastic Agents/therapeutic use ; Bayes Theorem ; Biomarkers, Tumor/metabolism ; Data Interpretation, Statistical ; Humans ; Neoplasms/drug therapy ; Neoplasms/metabolism ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis.
Autorzy:
Schwarz RF; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
Ng CK; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom; Department of Oncology, Hutchison/MRC Research Centre, University of Cambridge, Cambridge, United Kingdom.
Cooke SL; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
Newman S; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
Temple J; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
Piskorz AM; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
Gale D; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
Sayal K; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
Murtaza M; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
Baldwin PJ; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.
Rosenfeld N; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom; Department of Oncology, Hutchison/MRC Research Centre, University of Cambridge, Cambridge, United Kingdom.
Earl HM; Department of Oncology, Hutchison/MRC Research Centre, University of Cambridge, Cambridge, United Kingdom; NIHR Cambridge Biomedical Research Centre, Cambridge, United Kingdom.
Sala E; University Department of Radiology, Addenbrooke's Hospital, Cambridge, United Kingdom.
Jimenez-Linan M; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.
Parkinson CA; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom; Department of Oncology, Hutchison/MRC Research Centre, University of Cambridge, Cambridge, United Kingdom.
Markowetz F; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom; Department of Oncology, Hutchison/MRC Research Centre, University of Cambridge, Cambridge, United Kingdom.
Brenton JD; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom; Department of Oncology, Hutchison/MRC Research Centre, University of Cambridge, Cambridge, United Kingdom.
Pokaż więcej
Źródło:
PLoS medicine [PLoS Med] 2015 Feb 24; Vol. 12 (2), pp. e1001789. Date of Electronic Publication: 2015 Feb 24 (Print Publication: 2015).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Alleles*
DNA, Neoplasm*
Drug Resistance, Neoplasm*
Genetic Variation*
Phylogeny*
Neoplasms, Glandular and Epithelial/*genetics
Ovarian Neoplasms/*genetics
Platinum/*therapeutic use
Aged ; Algorithms ; Carcinoma, Ovarian Epithelial ; Disease-Free Survival ; Female ; Humans ; Middle Aged ; Neoplasms, Glandular and Epithelial/drug therapy ; Neoplasms, Glandular and Epithelial/mortality ; Ovarian Neoplasms/drug therapy ; Ovarian Neoplasms/mortality
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Saliva samples are a viable alternative to blood samples as a source of DNA for high throughput genotyping.
Autorzy:
Abraham JE; Department of Oncology and Strangeway's Research Laboratory, University of Cambridge, Cambridge, UK. />Maranian MJ
Spiteri I
Russell R
Ingle S
Luccarini C
Earl HM
Pharoah PP
Dunning AM
Caldas C
Pokaż więcej
Źródło:
BMC medical genomics [BMC Med Genomics] 2012 May 30; Vol. 5, pp. 19. Date of Electronic Publication: 2012 May 30.
Typ publikacji:
Journal Article
MeSH Terms:
DNA/*blood
Genotyping Techniques/*methods
High-Throughput Nucleotide Sequencing/*methods
Saliva/*metabolism
Alleles ; Female ; Genotype ; Humans ; Polymorphism, Single Nucleotide/genetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Wyświetlanie 61-73 z 73

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies